Aura Biosciences Q3 2021 Earnings Report

Completed initial public offering to fund pivotal program for AU-011 in choroidal melanoma and earlier stage oncology pipeline.

Presented final data from Phase 1b/2 trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology’s Annual Meeting.

AU-011 is being developed for the first line treatment of indeterminate lesions and small choroidal melanoma, a life threatening and rare disease with no approved drugs.

Aura plans to select the route of administration and treatment regimen to initiate the pivotal program in the second half of 2022.